Atorvastatin therapy is associated with reduced levels of N-terminal prohormone brain natriuretic peptide and improved cardiac function in patients with heart failure

Clinical Cardiology

Volumn 31, Issue 10, 2008, Pages 478-481

  Stypmann, Jörg ^a   Schubert, Aurelien ^a   Welp, Henryk ^a   Schulte, Helmut ^a   Assmann, Gerd ^a   Breithardt, Günter ^a   Nofer, Jerzy Roch ^a,b  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Atorvastatin; Heart failure; N terminal prohormone brain natriuretic peptide

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ATORVASTATIN; PRAVASTATIN; SIMVASTATIN; ALDOSTERONE ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ECHOCARDIOGRAPHY; HEART EJECTION FRACTION; HEART FAILURE; HEART FUNCTION; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; ADULT; AGED; BODY MASS; CHEMOLUMINESCENCE; DIABETES MELLITUS; DRUG EFFECT; HEART LEFT VENTRICLE FUNCTION; LIPID BLOOD LEVEL; SMOKING HABIT; SYSTOLIC BLOOD PRESSURE;

ECHOCARDIOGRAPHY; FOLLOW-UP STUDIES; HEART FAILURE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOASSAY; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROTEIN PRECURSORS; PYRROLES; RETROSPECTIVE STUDIES; STROKE VOLUME; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 54549092622     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.20273     Document Type: Article

References (23)

1. Briel M, Nordmann AJ, Bucher HC: Statin therapy for prevention and treatment of acute and chronic cardiovascular disease: update on recent trials and metaanalyses. Curr Opin Lipidol 2005;16:601-605
2. Wilt TJ, Bloomfield HE, MacDonald R, Nelson D, Rutks I, et al.: Effectiveness of statin therapy in adults with coronary heart disease. Arch Intern Med 2004;164:1427-1436
3. Calabro P, Yeh ETH: The pleiotropic effects of statins. Curr Opin Cardiol 2005;20:542-546
4. Davignon J: Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004;109(Suppl III):39-43
5. Horwich TB, MacLellan WR, Fonarow GC: Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. J Am Coll Cardiol 2004;43:642-648
6. Mozaffarian D, Nye R, Levy WC: Statin therapy is associated with lower mortality among patients with severe heart failure. Am J Cardiol 2004;93:1124-1129
7. Fukuta H, Sane DC, Brucks S, Little WC: Statin therapy may be associated with lower mortality in patients with diastolic heart failure. A preliminary report. Circulation 2005;112:357-363
8. Node K, Fujita M, Kitakaze M, Hori M, Liao JK: Short-term statin therapy improves cardiac function and symptoms in patients with idiopatic dilated cardiomyopathy. Circulation 2003;108:839-843
9. Laufs U, Wassmann S, Schackmann S, Heeschen C, Böhm M, et al.: Beneficial effects of statins in patients with non-ischaemic heart failure. Z Kardiol 2004;93:103-108
10. Wojnicz R, Wilczek K, Nowalany-Kozielska E, Szygula-Jurkiewicz B, Nowak J, et al.: Usefulness of atorvastatin in patients with heart failure due to inflammatory dilated cardiomyopathy and elevated cholesterol levels. Am J Cardiol 2006;97:899-904
11. Rothenburger M, Stypmann J, Bruch C, Wichter T, Hoppe M, et al.: Amonoterminal B-type pro-natriuretic peptide as a marker of recovery after high-risk coronary artery bypass grafting in patients with ischaemic heart disease and severe impaired left ventricular function. J Heart Lung Transplant 2006;25:596-602
12. Gottdiener JS, Bednarz J, Devereux R, Gardin J, Klein A, et al.: American Society of Echocardiography recommendations for use of echocardiography in clinical trials. J Am Soc Echocardiogr 2004;17: 1086-1119
13. Cheitlin MD, Armstrong WF, Aurigemma GP, Beller GA, Bierman FZ, et al.: ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography - summary article: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). J Am Coll Cardiol 2003;42:954-970
14. Trochu JN, Mital S, Zhang X, Xu X, Ochoa M, et al.: Preservation of NO production by statins in the treatment of heart failure. Cardiovasc Res 2003;60:250-258
15. Landmesser U, Engberding N, Bahlmann FH, Schaefer A, Wiencke A, et al.: Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase. Circulation 2004; 110: 1933-1939
16. Schafer A, Fraccarollo D, Eigenthaler M, Tas P, Firnschild A, et al.: Rosuvastatin reduces platelet activation in heart failure: role of NO bioavailability. Arterioscler Thromb Vasc Biol 2005;25:1071-1077
17. Mozaffarian D, Minami E, Letterer R, Lawler RL, McDonald GB, et al.: The effects of atorvastatin (10 mg) on systemic inflammation in heart failure. Am J Cardiol 2005;96:1699-1704
18. Strey CH, Young JM, Lainchbury JH, Frampton CM, Nicholls MG, et al.: Short-term statin therapy improves endothelial function and neurohormonal imbalance in normocholesteraemic patients with non-ischaemic heart failure. Heart 2006;92:1603-1609
19. Wiklund O, Matsson-Hulten E, Hurt-Camejo R, Oscarsson J: Effects of simvastatin and atorvastatin on inflammation markers in plasma. J Intern Med 2002;251:338-347
20. Schaefer EJ, McNamara JR, Asztalos BF, Tayler T, Daly JA, et al.: Effects of atorvastatin versus other statins on fasting and postprandial C-reactive protein and lipoprotein-associated phospholipase A2 in patients with coronary heart disease versus control subjects. Am J Cardiol 2005;95:1025-1032
21. Fichtlscherer S, Schmidt-Lucke C, Bojunga S, Rossig L, Heeschen C, et al.: Differential effects of short-term lipid lowering with ezetimibe and statins on endothelial function in patients with CAD: clinical evidence for 'pleiotropic' functions of statin therapy. Eur Heart J 2006;27:1182-1190
22. Tavazzi L, Tognoni G, Franzosi MG, Latini R, Maggioni AP, et al., GISSI-HF Investigators: Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. Eur J Heart Fail 2004;6:635-641
23. Kjekshus J, Dunselman P, Blideskog M, Eskilson C, Hjalmarson A, et al.: CORONA Study Group: A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): study design and baseline characteristics. Eur J Heart Fail 2005;7:1059-1069